Varian to Acquire Oncozene and Embozene Embolic Bead Lines From Boston Scientific
July 2, 2019—Varian Medical Systems, Inc. continued to expand its interventional oncology/embolic portfolio, announcing plans to acquire Boston Scientific's drug-loadable microsphere and bland embolic bead product lines for treating arteriovenous malformations and hypervascular tumors.
QXMédical Licenses Bioresorbable Embolic Technology From University of Minnesota
June 10, 2019—QXMédical announced that it has acquired the worldwide exclusive rights to the bioresorbable embolic technology developed at the University of Minnesota for resorbable and drug-loadable microspheres and hydrogels to be marketed to interventional radiologists and oncologists to occlude vessels for a variety of clinical indications.
FDA Approves DIRECT Study of AngioDynamics' NanoKnife to Treat Stage 3 Pancreatic Cancer
April 3, 2019—AngioDynamics, Inc. announced FDA approval of an investigational device exemption (IDE) application for the DIRECT clinical study of the company's NanoKnife irreversible electroporation direct cancer treatment.
Global Registry Will Collect Real-World Data on Liver Lesions Treated With Ethicon's NeuWave Microwave Ablation System
March 25, 2019—Ethicon, part of Johnson & Johnson Medical Devices Companies, has launched a new global registry to collect and analyze real-world data on patients with soft tissue liver lesions ablated with the company's NeuWave microwave ablation system.
Small Comparative Study Finds Patients Prefer Transradial Access Over Transfemoral Access
February 28, 2019—A recently published study found that patients favored transradial access (TRA) over transfemoral access (TFA) after experiencing both during the research period (22 [73.3%] vs 4 [13.3%] patients).
Guerbet's Lipiodol Ultra Fluid Approved for New Indication in cTACE
September 18, 2018—Guerbet LLC announced that it has been granted approval for a new indication for the company's Lipiodol Ultra Fluid in Belgium, Ireland, Portugal, Hong Kong, and the Philippines, for selective hepatic intra-arterial injection for visualization, localization, and vectorization during conventional transarterial chemoembolization (cTACE) of tumors in adults with known, intermediate-stage hepatocellular carcinoma (HCC).
Embolx's Next-Generation Sniper Balloon Occlusion Microcatheters Approved in Europe
September 5, 2018—Embolx, Inc., which develops microcatheters for arterial embolization procedures, announced CE Mark certifications for its next-generation Sniper balloon occlusion microcatheters designed to deliver pressure-directed arterial embolization therapy to treat cancerous tumors, enlarged prostate, and uterine fibroids.
FDA Grants Breakthrough Therapy Designation for Genentech's Tecentriq in Combination With Avastin as First-Line Treatment for Advanced or Metastatic HCC
July 18, 2018—Genentech, a member of the Roche Group, announced that the FDA has granted Breakthrough Therapy Designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab; Genentech) as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma (HCC).
Mentors and Protégés: Conversations on Career and Craft With Riad Salem, MD
Alexander Logsdon, DO, and Adam Sucher, DO, talk with Dr. Salem about balancing research and clinical responsibilities, his journey in establishing Y-90 as a standard of care, and his advice to aspiring clinical researchers, among other topics.
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in Europe.